South Africa’s Afrigen eyes Ebola vaccine role after landmark GMP certification

AI Summary

South Africa’s Afrigen biotech lab has achieved landmark GMP certification and is participating in developing an Ebola vaccine as the outbreak spreads from the Democratic Republic of the Congo into Uganda. This development is crucial for public health efforts in the region.

As the Ebola outbreak in Democratic Republic of the Congo crosses into Uganda, South Africa’s Afrigen biotech laboratory is participating in proposals to develop an effective vaccine.